Spots Global Cancer Trial Database for cytarabine
Every month we try and update this database with for cytarabine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00335140 | Lymphoma | Rituximab Cytarabine Dexamethasone Leucovorin Methotrexate Procarbazine Vincristine | 18 Years - | Eastern Cooperative Oncology Group | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | NCT00487448 | Myelodysplastic... Acute Myeloblas... | Fludarabine Cytarabine G-CSF Idarubicin Peripheral bloo... Bone marrow tra... | - 75 Years | PETHEMA Foundation | |
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | NCT05365035 | Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Venetoclax Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT01636609 | Acute Myeloid L... High Risk Myelo... | Azacitidine Cytarabine Tosedostat | 60 Years - | M.D. Anderson Cancer Center | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | NCT01476839 | Recurrent Adult... | basiliximab carmustine etoposide cytarabine melphalan pharmacological... laboratory biom... autologous hema... yttrium Y 90-la... | 18 Years - 70 Years | City of Hope Medical Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Freiburg ZNS-NHL Study | NCT00647049 | Primary Non Hod... | methotrexate Rituximab Cytarabine Thiotepa Carmustin | 18 Years - 65 Years | University Hospital Freiburg | |
| Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | NCT00040690 | Leukemia Lymphoma | filgrastim cyclophosphamid... cytarabine doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate vincristine sul... radiation thera... | 16 Years - | National Cancer Institute (NCI) | |
| NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | NCT01451515 | Lymphoblastic L... | Prednisone Vincristine Daunorubicin PEG-asparaginas... Erwinia asparag... Doxorubicin Cyclophosphamid... Cytarabine Thioguanine Clofarabine Methotrexate Mercaptopurine Dexamethasone Hydrocortisone Etoposide | - 21 Years | St. Jude Children's Research Hospital | |
| BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment | NCT00632749 | Leukemia, Myelo... | BI 811283 (d 1 ... Cytarabine BI 811283 (d1) Cytarabine | 18 Years - | Boehringer Ingelheim | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | NCT06210750 | T Acute Lymphob... T Lymphoblastic... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia | NCT00002785 | Leukemia | filgrastim asparaginase cyclophosphamid... cyclosporine cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... mercaptopurine mesna methotrexate methylprednisol... pegaspargase prednisone therapeutic hyd... vincristine sul... allogeneic bone... low-LET cobalt-... low-LET photon ... | - 1 Year | Children's Oncology Group | |
| Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia | NCT00049569 | L1 Childhood Ac... L2 Childhood Ac... Non-T, Non-B Ch... Recurrent Child... T-cell Childhoo... | cytarabine methotrexate vincristine sul... prednisone pegaspargase doxorubicin hyd... imatinib mesyla... cyclophosphamid... etoposide filgrastim leucovorin calc... asparaginase therapeutic hyd... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| A Study in Adults With Untreated Acute Lymphoblastic Leukemia | NCT00136435 | Acute Lymphobla... | prednisone doxorubicin vincristine methotrexate asparaginase dexamethasone cranial radiati... leucovorin cytarabine hydrocortisone 6-mercaptopurin... e. coli L-aspar... | 18 Years - 50 Years | Dana-Farber Cancer Institute | |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02299518 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... | mitoxantrone hy... etoposide cytarabine selinexor laboratory biom... pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01527149 | Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle... | Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul... | 18 Years - 70 Years | Roswell Park Cancer Institute | |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | NCT04217278 | Acute Myeloid L... High-risk Myelo... | Vyxeos Fludarabine Busulphan Thiotepa Cytarabine | 18 Years - | University of Birmingham | |
| Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | NCT00613457 | Leukemia | dexamethasone asparaginase Asparaginase cyclophosphamid... cytarabine daunorubicin doxorubicin Etoposide Ifosfamide mercaptopurine Methotrexate prednisone thioguanine Vincristine Vindesine | 1 Year - 17 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00003602 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin mitoxantrone hy... | 55 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | NCT00004905 | Leukemia | filgrastim recombinant int... cyclophosphamid... cytarabine etoposide idarubicin peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT01238211 | Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Core Binding Fa... Secondary Acute... Therapy-Related... | Cytarabine Dasatinib Daunorubicin Hy... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | NCT00270881 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | Cord blood tran... TBI cyclophosphamid... cytarabine | 20 Years - 55 Years | Keio University | |
| Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML | NCT00195104 | Myelodysplastic... | Arsenic Trioxid... Cytarabine | 18 Years - | Weill Medical College of Cornell University | |
| Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | NCT00004128 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | NCT00015951 | Leukemia Myelodysplastic... | bevacizumab cytarabine mitoxantrone hy... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) | NCT01444742 | Leukemia Myeloproliferat... | Clofarabine Cytarabine | 18 Years - | M.D. Anderson Cancer Center | |
| ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | NCT03286634 | Down Syndrome Acute Lymphobla... Childhood Cance... | Daunorubicin Prednisolone Vincristine Epirubicin E-coli L-aspara... 6-Mercaptopurin... Methotrexate Hydrocortisone Cytarabine Cyclophosphamid... | 0 Years - 20 Years | National Hospital Organization Nagoya Medical Center | |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | NCT00408005 | T Acute Lymphob... T Lymphoblastic... | Asparaginase Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Nelarabine Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul... | 1 Year - 30 Years | National Cancer Institute (NCI) | |
| Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma | NCT02840539 | Mantle Cell Lym... | Bortezomib, Cyt... | 18 Years - | Seoul National University Hospital | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT00004862 | Leukemia | filgrastim oblimersen sodi... cytarabine fludarabine pho... | 16 Years - | National Cancer Institute (NCI) | |
| 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02472626 | Untreated Adult... | 6,8-Bis(benzylt... Cytarabine Daunorubicin Hy... | 60 Years - | Wake Forest University Health Sciences | |
| Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00039117 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Secondary Acute... Untreated Adult... | oblimersen sodi... cytarabine daunorubicin hy... laboratory biom... pharmacological... | 60 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma | NCT00275106 | Lymphoma | asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone doxorubicin hyd... leucovorin calc... mercaptopurine methotrexate prednisolone thioguanine vincristine sul... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | NCT02212561 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Mixed Phenotype... | Selinexor Fludarabine Cytarabine methotrexate/hy... | - 24 Years | St. Jude Children's Research Hospital | |
| Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma | NCT03719560 | Diffuse Large B... | Methotrexate Cytarabine | 18 Years - | Brown University | |
| A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) | NCT04509622 | Acute Myeloid L... | Venetoclax Cytarabine | 18 Years - | AbbVie | |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | NCT02921061 | Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult... | Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | NCT02504359 | Plasma Cell Leu... Recurrent Plasm... | Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus | 18 Years - 65 Years | OHSU Knight Cancer Institute | |
| Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | NCT00381680 | B-cell Childhoo... L1 Childhood Ac... L2 Childhood Ac... Intermediate Ri... | vincristine sul... prednisone doxorubicin hyd... pegaspargase cytarabine methotrexate dexamethasone etoposide cyclophosphamid... leucovorin calc... filgrastim asparaginase mercaptopurine | 1 Year - 29 Years | Children's Oncology Group | |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT04898894 | Acute Leukemia ... Acute Myeloid L... Refractory Acut... Refractory Acut... | Venetoclax Selinexor Cytarabine Fludarabine Filgrastim Methotrexate methotrexate/hy... | 2 Years - 30 Years | St. Jude Children's Research Hospital | |
| Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | NCT00276809 | Chronic Lymphoc... | alemtuzumab filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT00002756 | Leukemia | filgrastim asparaginase cyclophosphamid... cytarabine daunorubicin hy... etoposide leucovorin calc... mercaptopurine methotrexate prednisone therapeutic hyd... vincristine sul... | - 1 Year | Children's Oncology Group | |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | NCT02981628 | Recurrent B Acu... Recurrent B Lym... Refractory B Ac... Refractory B Ly... | Asparaginase Er... Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cyclophosphamid... Cytarabine Diagnostic Imag... Inotuzumab Ozog... Leucovorin Calc... Lumbar Puncture Methotrexate Pegaspargase Vincristine | 1 Year - 21 Years | Children's Oncology Group | |
| Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT00778375 | Acute Myeloid L... Myelodysplastic... | Clofarabine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | NCT01627041 | Acute Myeloid L... Adult Acute Bas... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Alkylating Agen... Secondary Acute... | Cytarabine Daunorubicin Hy... Decitabine Laboratory Biom... Pharmacological... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT03860844 | Acute Lymphobla... Acute Myeloid L... | Isatuximab Dexamethasone o... Fludarabine Cytarabine Liposomal dauno... Daunorubicin (n... Idarubicin Filgrastim or e... Mitoxantrone Doxorubicin Vincristine Pegaspargase (P... Cyclophosphamid... Etoposide Methotrexate L - Asparginase Hydroxyurea L - Asparaginas... | 28 Days - 17 Years | Sanofi | |
| Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | NCT00003217 | Leukemia Lymphoma | filgrastim cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... methotrexate vincristine sul... | - 21 Years | Children's Oncology Group | |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | NCT02101853 | Recurrent B Acu... | Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | NCT00703820 | Acute Myeloid L... | Cytarabine Daunorubicin Etoposide Clofarabine CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00005601 | Lymphoma | rituximab cisplatin cytarabine dexamethasone sargramostim | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | NCT00542971 | AML Acute Myeloid L... Myelodysplastic... | Idarubicin Sorafenib Ara-C | 15 Years - 60 Years | M.D. Anderson Cancer Center | |
| Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00007852 | Lymphoma | rituximab carmustine cytarabine etoposide melphalan autologous hema... | 19 Years - | University of Nebraska | |
| A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02532192 | Lymphoma | Belinostat Rituximab Cisplatin Cytarabine Dexamethasone Ciprofloxacin Fluconazole | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03019640 | Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo... | Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab | 15 Years - 70 Years | M.D. Anderson Cancer Center | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | NCT03381781 | Acute Myeloid L... P53 Mutation | Decitabine Arsenic Trioxid... Cytarabine | 18 Years - 75 Years | Ruijin Hospital | |
| Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | NCT03897127 | Acute Myeloid L... | Cytarabine Daunorubicin CPX-351 | 18 Years - | University of Ulm | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT00053131 | Leukemia | filgrastim sargramostim cytarabine mitoxantrone hy... | 15 Years - | Roswell Park Cancer Institute | |
| Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | NCT05362942 | Relapsed Acute ... Refractory Acut... Minimal Residua... | Venetoclax, Dec... | 18 Years - | Beijing 302 Hospital | |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | NCT03488225 | Acute Lymphobla... B Acute Lymphob... B Acute Lymphob... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 16 Years - | M.D. Anderson Cancer Center | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | NCT00671658 | Leukemia Acute Lymphobla... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Dexamethasone Methotrexate (M... Cytarabine G-CSF Mesna Pegylated aspar... Pegfilgrastim Solumedrol | - | M.D. Anderson Cancer Center | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | NCT02310321 | Acute Myeloid L... FLT3-mutated Ac... | gilteritinib Idarubicin Cytarabine | 18 Years - 69 Years | Astellas Pharma Inc | |
| Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | NCT00093483 | Leukemia | filgrastim arsenic trioxid... cytarabine idarubicin | 18 Years - 59 Years | Roswell Park Cancer Institute | |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | NCT03900949 | Acute Myeloid L... | Allogeneic Hema... Cytarabine Daunorubicin Hy... Gemtuzumab Ozog... Midostaurin | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | NCT02983097 | Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Burkitt Lymphom... Aggressive Marg... | Rituximab Cisplatin Carboplatin Dexamethasone Cytarabine Lenalidomide PegFilgrastim peripheral stem... | 18 Years - 70 Years | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A | NCT01858922 | Hodgkin Disease | ABVE-PC DECA | - | Baylor College of Medicine | |
| Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT00002744 | Leukemia | asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone doxorubicin hyd... mercaptopurine methotrexate pegaspargase prednisone therapeutic hyd... thioguanine vincristine sul... low-LET cobalt-... low-LET photon ... | 1 Year - 9 Years | Children's Oncology Group | |
| S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00066794 | Leukemia | filgrastim sargramostim cyclosporine cytarabine daunorubicin hy... | 56 Years - | SWOG Cancer Research Network | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002761 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cyclosporine cytarabine idarubicin peripheral bloo... | 18 Years - 60 Years | Columbia University | |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | NCT02881086 | Acute Lymphobla... Lymphoblastic L... | Rituximab Nelarabine PEG-Asparaginas... Cranial irradia... Imatinib Idarubicin Dexamethasone Cyclophosphamid... Fludarabine Vincristine Mercaptopurine VP16 Daunorubicin (D... Methotrexate Stem cell trans... Cytarabine Vindesine Adriamycin Prednisolone | 18 Years - 55 Years | Goethe University | |
| Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma | NCT00004192 | Lymphoma Neutropenia | filgrastim pegfilgrastim cisplatin cytarabine etoposide methylprednisol... | 18 Years - 120 Years | University of Nebraska |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
